Frampton Surgery Limited - Accounts to registrar (filleted)

REGISTERED NUMBER: 13705825 (England and Wales)

Unaudited Financial Statements for the Year Ended 31st October 2025

for

Frampton Surgery Limited

Page

Balance Sheet

1

Notes to the Financial Statements

2

FIXED ASSETS

Tangible assets

4

496

-

CURRENT ASSETS

Investments

5

25,945

-

Cash at bank

12,046

16,792

37,991

16,792

CREDITORS

Amounts falling due within one year

6

25,564

13,352

NET CURRENT ASSETS

12,427

3,440

TOTAL ASSETS LESS CURRENT
LIABILITIES

12,923

3,440

PROVISIONS FOR LIABILITIES

94

-

NET ASSETS

12,829

3,440

CAPITAL AND RESERVES

Called up share capital

7

101

Retained earnings

12,728

3,339

SHAREHOLDERS' FUNDS

12,829

3,440

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st October 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st October 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 15th July 2026 and were signed on its behalf by:

Dr A Frampton - Director

1.	COMPANY INFORMATION

Frampton Surgery Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number:

13705825

Registered office:

Second Floor

The Lexicon

Mount Street

Manchester

M2 5NT

The presentation currency of the financial statements is the Pound Sterling (£).

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Revenue from the provision of professional services is recognised on delivery of the service.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Tangible fixed assets are included at cost less depreciation and impairment. Depreciation has been computed to write off the cost of tangible fixed assets over their expected useful life.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2024 - 2 ) .

4.	TANGIBLE FIXED ASSETS

Fixtures

and

fittings

£

COST

Additions

541

At 31st October 2025

541

DEPRECIATION

Charge for year

45

At 31st October 2025

45

NET BOOK VALUE

At 31st October 2025

496

5.	CURRENT ASSET INVESTMENTS

Market value of listed investments at 31 October 2025 - £25,945 (2024 - £NIL). The current asset investments represents holdings in listed shares. The listed shares are recognised at market value.

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.10.25

31.10.24

£

Tax

22,336

10,673

Directors' current accounts

836

1,051

Accrued expenses

2,392

1,628

25,564

13,352

7.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

31.10.25

31.10.24

value:

£

100

Ordinary A

£1

100

1

Ordinary B

£1

1

101

The A and B Shares confer on the holders the right to vote upon any resolution proposed at any general meeting of the company.

The A and B Shares rank pari passu in respect of dividend and capital distribution rights.

8.	DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 31st October 2025 and 31st October 2024:

31.10.25

31.10.24

£

Dr A Frampton

Balance outstanding at start of year

(1,051

)

(83

)

Amounts advanced

71,091

58,325

Amounts repaid

(70,876

)

(59,293

)

Amounts written off

-

Amounts waived

-

Balance outstanding at end of year

(836

)

(1,051

)

The loan is repayable on demand and no interest was charged during the year.

9.	ULTIMATE CONTROLLING PARTY

The controlling party is Dr A Frampton.